The Medical Device Business Journal — Medical Device News & Articles | MassDevice
There’s no pleasing some people. Abbott (NYSE:ABT) shares were down on Wall Street today, despite the health care products giant reporting strong second-quarter sales and earnings figures — including a nearly 100 percent top-line surge for its coronary stents business.
Intuitive Surgical Inc. (NSDQ:ISRG) announced another expectation-defying quarter, reporting a 21 percent jump in sales and a 32 percent leap in profits for the second quarter ended June 30.
The Sunnyvale, Calif.-based company posted earnings of $117.4 million on $425.7 million in sales for the quarter, compared to $88.7 million on $350.7 million in sales during the same period last year. That translates into a 33 percent jump for diluted earnings per share, which rose to $2.91 from $2.19 during Q2 2010.
Stryker Corp.’s (NYSE:SYK) second-quarter sales slid more than 3 percent, despite a top-line rise of 16.3 percent, as the Kalamazoo, Mich.-based medical device maker digested a pair of big acquisitions.
Stryker posted earnings of $309 million, or 79 cents per diluted share, on sales of $2.05 billion during the three months ended June 30. That compares with profits of $319 million, or 80 cents diluted EPS, on sales of $1.76 billion during the same period last year.
There’s no pleasing some people. Abbott (NYSE:ABT) shares were down on Wall Street today, despite the health care products giant reporting strong second-quarter sales and earnings figures — including a nearly 100 percent top-line surge for its coronary stents business.
Johnson & Johnson (NYSE:JNJ) managed to top Wall Street’s expectations with its second-quarter results, despite posting a nearly 20 percent bottom-line slide.
The New Brunswick, N.J.-based health care products conglomerate reported profits of $2.78 billion, or $1.00 per diluted share, on sales of $16.60 billion for the three months ended March 30.
Losses for Biomet Inc., a bellwether for the U.S. orthopedic market, soared during the fourth quarter and fiscal 2011, largely due to a nearly $1 billion writedown related to its re-assessment of the European market.
Second-quarter sales and earnings may have slipped for Swedish medical device maker Getinge AB (STO:GETI B), but that hasn’t stopped it from issuing an ambitious plan to boost its profits.
Abbott (NYSE:ABT) posted flat second-quarter earnings despite a nearly 18 percent increase to its top line.
The Abbott Park, Ill.-based medical products conglomerate reported sales of $8.83 billion for the three months ended June 30, up 17.8 percent compared with $7.50 billion during the same period last year. But net earnings were flat at $1.29 billion, or 83 cents per diluted share, compared with the same numbers during Q2 2009.
Covidien plc (NYSE:COV) restated its financial results for the past two quarters after it re-classified its specialty chemicals business, sold to New Mountain Capital LLC last month, as a discontinued operation.
The Mansfield, Mass.-based medical products conglomerate had posted first-quarter sales of $2.75 billion during the three months ended Dec. 25, 2009. But after deducting $105 million in discontinued sales, the company is reporting Q1 sales of $2.64 billion, down 3.8 percent.
